Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2008

Open Access 01-12-2008 | Research

Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1

Authors: John Lowe, Debasis Panda, Suzanne Rose, Ty Jensen, Willie A Hughes, For Yue Tso, Peter C Angeletti

Published in: Virology Journal | Issue 1/2008

Login to get access

Abstract

Background

PVs (PV) are small, non-enveloped, double-stranded DNA viruses that have been identified as the primary etiological agent for cervical cancer and their potential for malignant transformation in mucosal tissue has a large impact on public health. The PV family Papillomaviridae is organized into multiple genus based on sequential parsimony, host range, tissue tropism, and histology. We focused this analysis on the late gene products, major (L1) and minor (L2) capsid proteins from the family Papillomaviridae genus Alpha-papillomavirus. Alpha-PVs preferentially infect oral and anogenital mucosa of humans and primates with varied risk of oncogenic transformation. Development of evolutionary associations between PVs will likely provide novel information to assist in clarifying the currently elusive relationship between PV and its microenvironment (i.e., the single infected cell) and macro environment (i.e., the skin tissue). We attempt to identify the regions of the major capsid proteins as well as minor capsid proteins of alpha-papillomavirus that have been evolutionarily conserved, and define regions that are under constant selective pressure with respect to the entire family of viruses.

Results

This analysis shows the loops of L1 are in fact the most variable regions among the alpha-PVs. We also identify regions of L2, involved in interaction with L1, as evolutionarily conserved among the members of alpha- PVs. Finally, a predicted three-dimensional model was generated to further elucidate probable aspects of the L1 and L2 interaction.
Appendix
Available only for authorised users
Literature
1.
de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004,324(1):17-27. 10.1016/j.virol.2004.03.033CrossRefPubMed
2.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003,348(6):518-527. 10.1056/NEJMoa021641CrossRefPubMed
3.
Cain JM, Howett MK: Preventing cervical cancer. Science 2000,288(5472):1753-1755. 10.1126/science.288.5472.1753CrossRefPubMed
4.
Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995,87(11):796-802. 10.1093/jnci/87.11.796CrossRefPubMed
5.
Munger K, Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res 2002,89(2):213-228. 10.1016/S0168-1702(02)00190-9CrossRefPubMed
6.
Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC: Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000,5(3):557-567. 10.1016/S1097-2765(00)80449-9CrossRefPubMed
7.
Lowy DR, Howley PM: Papillomaviruses. In Fields Virology. Volume 2. Edited by: Knipe DM HP, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE. Baltimore, MD: Lippinkot Williams & Wilkins; 2001:2231-2264.
8.
Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992,89(24):12180-12184. 10.1073/pnas.89.24.12180PubMedCentralCrossRefPubMed
9.
Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT: Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993,67(12):6929-6936.PubMedCentralPubMed
10.
Chen XS, Casini G, Harrison SC, Garcea RL: Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol 2001,307(1):173-182. 10.1006/jmbi.2000.4464CrossRefPubMed
11.
Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS: Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 2007,282(43):31803-31811. 10.1074/jbc.M706380200CrossRefPubMed
12.
Christensen ND, Kreider JW: Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990,64(7):3151-3156.PubMedCentralPubMed
13.
Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL: Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998,72(7):6151-6154.PubMedCentralPubMed
14.
White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, Hewitt LA, Goldman DM, Burke SJ, Jenson AB, Koenig S, et al.: Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 1999,73(6):4882-4889.PubMedCentralPubMed
15.
Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, Skulsky DM, McClements WL, Ludmerer SW, Jansen KU: Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 2001,291(2):324-334. 10.1006/viro.2001.1220CrossRefPubMed
16.
Ludmerer SW, Benincasa D, Mark GE 3rd, Christensen ND: A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol 1997,71(5):3834-3839.PubMedCentralPubMed
17.
Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL: Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol 1997,71(4):2988-2995.PubMedCentralPubMed
18.
Zhou J, Sun XY, Louis K, Frazer IH: Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. J Virol 1994,68(2):619-625.PubMedCentralPubMed
19.
Finnen RL, Erickson KD, Chen XS, Garcea RL: Interactions between papillomavirus L1 and L2 capsid proteins. J Virol 2003,77(8):4818-4826. 10.1128/JVI.77.8.4818-4826.2003PubMedCentralCrossRefPubMed
20.
Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T: Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 1999,73(7):6188-6190.PubMedCentralPubMed
21.
Embers ME, Budgeon LR, Pickel M, Christensen ND: Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002,76(19):9798-9805. 10.1128/JVI.76.19.9798-9805.2002PubMedCentralCrossRefPubMed
22.
Kawana Y, Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T: Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol 2001,75(5):2331-2336. 10.1128/JVI.75.5.2331-2336.2001PubMedCentralCrossRefPubMed
23.
Liu WJ, Gissmann L, Sun XY, Kanjanahaluethai A, Muller M, Doorbar J, Zhou J: Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology 1997,227(2):474-483. 10.1006/viro.1996.8348CrossRefPubMed
24.
Büchen-Osmond C: Index of Viruses – Papillomaviridae. 2006.
25.
Edgar RC: MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 2004, 5: 113. 10.1186/1471-2105-5-113PubMedCentralCrossRefPubMed
26.
27.
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al.: Clustal W and Clustal X version 2.0. Bioinformatics 2007,23(21):2947-2948. 10.1093/bioinformatics/btm404CrossRefPubMed
28.
29.
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res 2000,28(1):235-242. 10.1093/nar/28.1.235PubMedCentralCrossRefPubMed
30.
Bates PA, Kelley LA, MacCallum RM, Sternberg MJ: Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins 2001, (Suppl 5):39-46. 10.1002/prot.1168
31.
Karplus K, Barrett C, Hughey R: Hidden Markov models for detecting remote protein homologies. Bioinformatics 1998,14(10):846-856. 10.1093/bioinformatics/14.10.846CrossRefPubMed
32.
Karplus K, Karchin R, Barrett C, Tu S, Cline M, Diekhans M, Grate L, Casper J, Hughey R: What is the value added by human intervention in protein structure prediction? Proteins 2001, (Suppl 5):86-91. 10.1002/prot.10021
33.
Karplus K, Karchin R, Draper J, Casper J, Mandel-Gutfreund Y, Diekhans M, Hughey R: Combining local-structure, fold-recognition, and new fold methods for protein structure prediction. Proteins 2003,53(Suppl):491-496. 10.1002/prot.10540CrossRefPubMed
34.
Karplus K, Katzman S, Shackleford G, Koeva M, Draper J, Barnes B, Soriano M, Hughey R: SAM-T04: what is new in protein-structure prediction for CASP6. Proteins 2005,61(Suppl 7):135-142. 10.1002/prot.20730CrossRefPubMed
35.
Bower MJ, Cohen FE, Dunbrack RL Jr: Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J Mol Biol 1997,267(5):1268-1282. 10.1006/jmbi.1997.0926CrossRefPubMed
36.
Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P: Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002,76(13):6480-6486. 10.1128/JVI.76.13.6480-6486.2002PubMedCentralCrossRefPubMed
37.
Comeau SR, Gatchell DW, Vajda S, Camacho CJ: ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res 2004, (32 Web Server):W96-W99. 10.1093/nar/gkh354
38.
Comeau SR, Gatchell DW, Vajda S, Camacho CJ: ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics 2004,20(1):45-50. 10.1093/bioinformatics/btg371CrossRefPubMed
39.
Comeau SR, Kozakov D, Brenke R, Shen Y, Beglov D, Vajda S: ClusPro: performance in CAPRI rounds 6–11 and the new server. Proteins 2007,69(4):781-785. 10.1002/prot.21795CrossRefPubMed
40.
Comeau SR, Vajda S, Camacho CJ: Performance of the first protein docking server ClusPro in CAPRI rounds 3–5. Proteins 2005,60(2):239-244. 10.1002/prot.20564CrossRefPubMed
41.
Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB: Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005,337(2):365-372. 10.1016/j.virol.2005.04.011CrossRefPubMed
42.
Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB: Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007,81(21):11585-11592. 10.1128/JVI.01577-07PubMedCentralCrossRefPubMed
43.
Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB: A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007,81(24):13927-13931. 10.1128/JVI.00936-07PubMedCentralCrossRefPubMed
44.
Chen XS, Stehle T, Harrison SC: Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. The EMBO journal 1998,17(12):3233-3240. 10.1093/emboj/17.12.3233PubMedCentralCrossRefPubMed
45.
Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA: Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996,223(1):174-184. 10.1006/viro.1996.0466CrossRefPubMed
46.
Ludmerer SW, Benincasa D, Mark GE 3rd: Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol 1996,70(7):4791-4794.PubMedCentralPubMed
47.
Ludmerer SW, McClements WL, Wang XM, Ling JC, Jansen KU, Christensen ND: HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology 2000,266(2):237-245. 10.1006/viro.1999.0083CrossRefPubMed
48.
McClements WL, Wang XM, Ling JC, Skulsky DM, Christensen ND, Jansen KU, Ludmerer SW: A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology 2001,289(2):262-268. 10.1006/viro.2001.1146CrossRefPubMed
49.
Wang Z, Christensen N, Schiller JT, Dillner J: A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 1997,78(Pt 9):2209-2215.CrossRefPubMed
50.
Garcia AM, Ortiz-Navarrete VF, Mora-Garcia ML, Flores-Borja F, Diaz-Quinonez A, Isibasi-Araujo A, Trejo-Becerril C, Chacon-Salinas R, Hernandez-Montes J, Granados-Arreola J, et al.: Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection. Immunol Lett 1999,67(3):167-177. 10.1016/S0165-2478(98)00188-6CrossRefPubMed
51.
Monroy-Garcia A, Weiss-Steider B, Hernandez-Montes J, Ortiz-Navarrete VF, Banuelos-Panuco A, Acosta-Araujo A, Diaz-Quinonez A, Lopez-Graniel CM, Herbert G, Granados J, et al.: Identification of two homologous antigenic peptides derived from L1 HPV-16 and 18 proteins specific for the HLA-B*3901 allele. Arch Virol 2002,147(10):1933-1942. 10.1007/s00705-002-0854-yCrossRefPubMed
52.
Shepherd PS, Rowe AJ, Cridland JC, Coletart T, Wilson P, Luxton JC: Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. J Gen Virol 1996,77(Pt 4):593-602. 10.1099/0022-1317-77-4-593CrossRefPubMed
53.
Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS, Lindahl U, Sapp M: Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J Biol Chem 2007,282(38):27913-27922. 10.1074/jbc.M705127200CrossRefPubMed
54.
Sapp M, Fligge C, Petzak I, Harris JR, Streeck RE: Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. J Virol 1998,72(7):6186-6189.PubMedCentralPubMed
55.
Touze A, Mahe D, El Mehdaoui S, Dupuy C, Combita-Rojas AL, Bousarghin L, Sizaret PY, Coursaget P: The nine C-terminal amino acids of the major capsid protein of the human papillomavirus type 16 are essential for DNA binding and gene transfer capacity. FEMS Microbiol Lett 2000,189(1):121-127.CrossRefPubMed
56.
Okun MM, Day PM, Greenstone HL, Booy FP, Lowy DR, Schiller JT, Roden RB: L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation. J Virol 2001,75(9):4332-4342. 10.1128/JVI.75.9.4332-4342.2001PubMedCentralCrossRefPubMed
57.
Barouch DH, Harrison SC: Interactions among the major and minor coat proteins of polyomavirus. J Virol 1994,68(6):3982-3989.PubMedCentralPubMed
58.
Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC: Immunological analyses of human papillomavirus capsids. Vaccine 2001,19(13–14):1783-1793. 10.1016/S0264-410X(00)00370-4CrossRefPubMed
59.
Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR: Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995,69(6):3959-3963.PubMedCentralPubMed
60.
Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995,92(25):11553-11557. 10.1073/pnas.92.25.11553PubMedCentralCrossRefPubMed
61.
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006,367(9518):1247-1255. 10.1016/S0140-6736(06)68439-0CrossRefPubMed
62.
Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, et al.: Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006,24(27–28):5571-5583. 10.1016/j.vaccine.2006.04.068CrossRefPubMed
63.
Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T: Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 2007,358(2):266-272. 10.1016/j.virol.2006.08.037CrossRefPubMed
64.
Kay BK, Williamson MP, Sudol M: The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. Faseb J 2000,14(2):231-241.PubMed
65.
Day PM, Roden RB, Lowy DR, Schiller JT: The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol 1998,72(1):142-150.PubMedCentralPubMed
66.
Florin L, Sapp C, Streeck RE, Sapp M: Assembly and translocation of papillomavirus capsid proteins. J Virol 2002,76(19):10009-10014. 10.1128/JVI.76.19.10009-10014.2002PubMedCentralCrossRefPubMed
Metadata
Title
Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1
Authors
John Lowe
Debasis Panda
Suzanne Rose
Ty Jensen
Willie A Hughes
For Yue Tso
Peter C Angeletti
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2008
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-5-150

Other articles of this Issue 1/2008

Virology Journal 1/2008 Go to the issue

Research

The herpesvirus 8 encoded chemokines vCCL2 (vMIP-II) and vCCL3 (vMIP-III) target the human but not the murine lymphotactin receptor

Research

Passive immunization against highly pathogenic Avian Influenza Virus (AIV) strain H7N3 with antiserum generated from viral polypeptides protect poultry birds from lethal viral infection

Research

Immune response during acute Chandipura viral infection in experimentally infected susceptible mice

Research

Molecular characterization and complete genome sequence of avian paramyxovirus type 4 prototype strain duck/Hong Kong/D3/75

Short report

Molecular characterization of Umbre virus (Bunyaviridae)

Research

Proteomics computational analyses suggest that baculovirus GP64 superfamily proteins are class III penetrenes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits